Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of “Moderate Buy” by Analysts

Sionna Therapeutics, Inc. (NASDAQ:SION) has received an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $53.2222.

Several analysts have recently weighed in on SION shares. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, May 13th. JonesTrading upped their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Stifel Nicolaus upped their target price on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a report on Monday, May 18th. Finally, Wedbush started coverage on Sionna Therapeutics in a report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 target price for the company.

Sionna Therapeutics Stock Up 0.5%

Shares of Sionna Therapeutics stock opened at $33.69 on Friday. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -17.46 and a beta of 1.30. The business has a fifty day simple moving average of $40.33 and a 200-day simple moving average of $39.82. Sionna Therapeutics has a fifty-two week low of $13.51 and a fifty-two week high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Analysts anticipate that Sionna Therapeutics will post -2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 184,639 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,717,962 shares of company stock valued at $77,571,889. 5.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds have recently modified their holdings of the stock. Deutsche Bank AG lifted its holdings in shares of Sionna Therapeutics by 4.5% during the fourth quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock valued at $413,000 after purchasing an additional 433 shares during the last quarter. Bank of America Corp DE raised its position in Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after buying an additional 529 shares during the period. MetLife Investment Management LLC raised its position in Sionna Therapeutics by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock valued at $352,000 after buying an additional 532 shares during the period. BNP Paribas Financial Markets raised its position in Sionna Therapeutics by 35.2% during the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in Sionna Therapeutics during the fourth quarter valued at $36,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.